Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Anastrozole (Primary) ; Everolimus (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms Treat ER+ight
- Sponsors Novartis Pharmaceuticals
- 06 Feb 2018 Planned End Date changed from 1 Dec 2019 to 2 Dec 2019.
- 06 Feb 2018 Planned primary completion date changed from 1 Dec 2019 to 2 Dec 2019.
- 11 Jan 2018 New trial record